# 2026年2月27日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 特考韦瑞治疗猴痘的临床研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41740032)
**期刊：** The New England journal of medicine
**PMID：** 41740032
**DOI：** 10.1056/NEJMoa2506495

### 第一部分 原文与翻译

**英文原标题：** Tecovirimat for the Treatment of Mpox.

> **英文摘要：**
> BACKGROUND: Tecovirimat is approved for smallpox treatment under the Food and Drug Administration Animal Rule on the basis of efficacy in nonhuman primate models of mpox (previously known as monkeypox). However, the clinical efficacy of tecovirimat against human clade II mpox is unclear.
> 
> METHODS: In a phase 3, international, double-blind, randomized, placebo-controlled trial, we evaluated the efficacy of oral tecovirimat in adults with laboratory-confirmed clade II mpox. Participants were randomly assigned in a 2:1 ratio to receive tecovirimat or placebo for 14 days. The primary outcome was clinical resolution, assessed in a time-to-event analysis in participants with active skin or mucosal lesions. Secondary outcomes included reduction in pain, assessed in all participants with laboratory-confirmed mpox and in those with severe pain at baseline (pain score, 7 to 10; scale, 0 [no pain] to 10 [worst pain imaginable]); complete lesion healing (assessed in a time-to-event analysis); viral DNA clearance; and safety.
> 
> RESULTS: Of 412 participants who underwent randomization (275 to tecovirimat and 137 to placebo), 344 had laboratory-confirmed mpox, and 336 had active skin or mucosal lesions and were included in the primary analysis. By day 29, the estimated cumulative incidence of clinical resolution was 83% with tecovirimat and 84% with placebo; the competing-risks hazard ratio for clinical resolution was 0.98 (95% confidence interval [CI], 0.74 to 1.31; P = 0.89). No substantial between-group differences were seen in pain reduction among participants with severe pain (difference, 0.1 point; 95% CI, -0.8 to 1.0), in complete lesion healing (competing-risks hazard ratio, 0.97; 95% CI, 0.75 to 1.26), or in viral DNA clearance. The incidence of adverse events of grade 3 or higher was similar in the two groups (4% with tecovirimat and 3% with placebo).
> 
> CONCLUSIONS: This trial showed no evidence that tecovirimat therapy shortened the time to clinical resolution, reduced pain, or increased viral clearance among adults with clade II mpox. (Funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; STOMP/A5418 ClinicalTrials.gov number, NCT05534984.).

> **中文摘要：**
> 【背景】特考韦瑞（Tecovirimat）是根据美国食品药品监督管理局（FDA）的“动物法则”，基于其在猴痘（此前称为 monkeypox）非人灵长类模型中的有效性而被批准用于天花治疗的。然而，特考韦瑞对抗人类分支 II（clade II）猴痘的临床疗效尚不明确。【方法】在一项 3 期、国际、双盲、随机、安慰剂对照试验中，我们评估了口服特考韦瑞在实验室确诊的分支 II 猴痘成人患者中的疗效。参与者按 2:1 的比例随机分配，接受特考韦瑞或安慰剂治疗 14 天。主要结局是临床缓解，在患有活动性皮肤或黏膜病变的参与者中进行事件发生时间分析。次要结局包括：在所有实验室确诊猴痘的参与者以及基线时有严重疼痛（疼痛评分 7 至 10 分；量表范围 0 [无痛] 至 10 [能想象的最剧烈疼痛]）的参与者中评估疼痛减轻情况；皮损完全愈合（通过事件发生时间分析评估）；病毒 DNA 清除率；以及安全性。【结果】在接受随机分组的 412 名参与者中（275 人分配至特考韦瑞组，137 人分配至安慰剂组），344 人确诊为猴痘，336 人有活动性皮肤或黏膜病变并被纳入主要分析。截至第 29 天，特考韦瑞组临床缓解的估计累积发生率为 83%，安慰剂组为 84%；临床缓解的竞争风险风险比（hazard ratio）为 0.98（95% 置信区间 [CI] 为 0.74 至 1.31；P = 0.89）。在严重疼痛参与者的疼痛减轻（差异为 0.1 分；95% CI 为 -0.8 至 1.0）、皮损完全愈合（竞争风险风险比为 0.97；95% CI 为 0.75 至 1.26）或病毒 DNA 清除方面，两组间均未见实质性差异。两组中 3 级或以上不良事件的发生率相似（特考韦瑞组为 4%，安慰剂组为 3%）。【结论】本试验显示，没有证据表明特考韦瑞疗法能缩短分支 II 猴痘成人患者的临床缓解时间、减轻疼痛或增加病毒清除。（该研究由美国国家卫生研究院国家过敏和传染病研究所资助；STOMP/A5418 ClinicalTrials.gov 编号为 NCT05534984。）

### 第二部分 AI 大师评价

这项 3 期随机对照试验（STOMP/A5418）对特考韦瑞治疗人类分支 II 猴痘的疗效进行了严格评估。尽管该药此前基于动物模型数据获批，但本研究在人体临床试验中并未发现其在缩短症状缓解时间、缓解疼痛或加速病毒清除方面优于安慰剂，结果具有重要的统计学意义和临床指导价值。该研究不仅为全球猴痘防治策略提供了高质量的循证医学证据，也再次凸显了“动物法则”批准药物在人类真实世界中进行验证性临床试验的重要性。

---

## 2. 肠道肉毒神经毒素促进沙门氏菌和柠檬酸杆菌的感染

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41739930)
**期刊：** Science advances
**PMID：** 41739930
**DOI：** 10.1126/sciadv.ady9407

### 第一部分 原文与翻译

**英文原标题：** Enteric botulinum neurotoxins facilitate infection by Salmonella and Citrobacter.

> **英文摘要：**
> Botulism is a life-threatening disease caused by botulinum neurotoxins (BoNTs) released by Clostridium bacteria. BoNTs induce a flaccid paralysis by blocking neurotransmitter release from peripheral cholinergic neurons via soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) cleavage. The enteric nervous system (ENS) controls antimicrobial defense reactions within the intestine through neuron-released mediators. Here, we show that subclinical doses of BoNT/A and BoNT/B, which are not sufficient to cause botulism when released in the intestinal lumen, paralyze ENS neurons favoring infection by prototypic bacterial pathogens such as Salmonella and Citrobacter. The BoNTs reduce the release of mucin, decreasing the protective barrier against bacterial infection. These findings disclose previously unrecognized functions of BoNTs and roles in intestinal infections. Moreover, they indicate that BoNTs are valuable tools for investigating the ENS neuron involvement in the intestinal defense reactions.

> **中文摘要：**
> 肉毒中毒是由肉毒杆菌释放的肉毒神经毒素 (BoNTs) 引起的一种危及生命的疾病。BoNTs 通过切割可溶性 N-乙基马来酰亚胺敏感因子附着蛋白受体 (SNARE)，阻断外周胆碱能神经元的神经递质释放，从而诱导迟缓性麻痹。肠道神经系统 (ENS) 通过神经元释放的介质控制肠道内的抗微生物防御反应。在本研究中，我们证明亚临床剂量的 BoNT/A 和 BoNT/B（当在肠腔内释放时不足以引起肉毒中毒）会使 ENS 神经元瘫痪，从而有利于沙门氏菌和柠檬酸杆菌等典型致病菌的感染。BoNTs 减少了粘蛋白的释放，削弱了针对细菌感染的保护屏障。这些发现揭示了 BoNTs 以前未被认识的功能及其在肠道感染中的作用。此外，研究表明 BoNTs 是研究 ENS 神经元参与肠道防御反应的有价值工具。

### 第二部分 AI 大师评价

该研究揭示了肉毒神经毒素（BoNTs）在传统致病机制之外的新功能，即通过麻痹肠道神经系统（ENS）削弱宿主的抗微生物防御。实验表明，亚临床剂量的 BoNT/A 和 BoNT/B 虽不足以引起全身性肉毒中毒，但能显著减少肠道粘蛋白分泌，从而为沙门氏菌等病原体侵袭创造条件。这一发现不仅深化了对肠道神经-免疫互作机制的理解，也为利用 BoNTs 作为分子工具研究 ENS 在肠道稳态中的作用提供了新思路。

---

速递结束，祝您工作愉快！